Neo-Gem

Closed

ANZ 0502: Neoadjuvant Gemcitabine

BCT Study Chair:

Frances Boyle

A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+ trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma.

0

INTERNATIONAL

Total number of trial

participants internationally

81

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

14

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

NEO-GEM PUBLICATIONS

2014

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF, on behalf of the Australia and New Zealand Breast Cancer Trials Group The Breast 2014; 23142-151, Journal

2011

ANZ 0502 NeoGem: A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide followed by docetaxel with gemcitabine (+ trastuzumab if HER2 positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma.

McCarthy N, Boyle F, Bull J, Leong E, Simpson A, Kannourakis G, Gebski V, Forbes JF, Wilcken N, Lindsay DF, Badger HD. On behalf of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG). 34th Annual San Antonio Breast Cancer Symposium, December 6 -10, 2011 San Antonio, Texas. 2011; P3-14-28, Poster

2006

Australian New Zealand Breast Cancer Trials Group: Translational research.

Forbes JF. HMRI Conference on Translational Research 2006; Poster P-06, Poster

Neo-Gem